Mechanism of p53-induced apoptosis

Biochemical Pharmacology

Volumn 58, Issue 7, 1999, Pages 1089-1095

  Bennett, Martin R ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Apoptosis; Cancer; Cell cycle; Oncogene; p53; Transcription

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER; CELL CYCLE; ONCOGENE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; ANIMAL; CELL CULTURE; HUMAN; PHYSIOLOGY; TRANSACTIVATION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELLS, CULTURED; HUMANS; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033201437     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00153-7     Document Type: Note

References (80)

1. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC and Vogelstein B, Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708, 1989.
2. Hollstein M, Sidransky D, Vogelstein B and Harris C, P53 mutations in human cancers. Science 253: 49-53, 1991.
3. Vogelstein B, Cancer. A deadly inheritance. Nature 348: 681-682, 1990.
4. Lane DP, P53, guardian of the genome. Nature 358: 15-16, 1992.
5. Canman CE and Kastan MB, Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis. Oncogene 16: 957-966, 1998.
6. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T and Neckers L, P53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273: 11995-11998, 1998.
7. Donato NJ and Perez M, Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells. J Biol Chem 273: 5067-5072, 1998.
8. waf1/cip1. Genes Dev 8: 2817-2830, 1994.
9. 1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
10. Prasad VS, LaFond RE, Zhou M, Jacobsen KA, Osmond DG and Sidman CL, Upregulation of endogenous p53 and induction of in vivo apoptosis in B-lineage lymphomas of Eμ-myc transgenic mice by deregulated C-myc transgene. Mol Carcinog 18: 66-77, 1997.
11. Yu K, Ravera CP, Chen Y-NP and McMahon G, Regulation of Myc-dependent apoptosis by p53, c-Jun N-terminal kinases/stress-activated protein kinases, and Mdm-2. Cell Growth Differ 8: 731-742, 1997.
12. Kowalik TF, DeGregori J, Leone G, Jakoi L and Nevins JR, E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 9: 113-118, 1998.
13. Phillips AC, BateS S, Ryan KM, Helin K and Vousden KH, Induction of DNA synthesis and apoptosis are separable functions of E2F-1. Genes Dev 11: 1853-1863, 1997.
14. Hsieh J-K, Fredersdorf S, Kouzarides T, Martin K and Lu X, E2F1-induced apoptosis requires DNA binding but not trans-activation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev 11: 1840-1852, 1997.
15. Hunt KK, Deng J, Liu T-J, Wilson-Heiner M, Swisher SG, Clayman G and Hung M-C, Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. Cancer Res 57: 4722-4726, 1997.
16. Chiou SK and White E, P300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. J Virol 71: 3515-3525, 1997.
17. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC, Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
18. Selvakumaran M, Lin H-K, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B and Liebermann D, Immediate early up-regulation of bax expression by p53 but not TGFβ1: A paradigm for distinct apoptotic pathways. Oncogene 9: 1791-1798, 1994.
19. Miyashita T, Harigai M, Hanada M and Reed JC, Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135, 1994.
20. Buckbinder L, Talbott R, Velascomiguel S, Takenaka I, Faha B, Seizinger B and Kley N, Induction of the growth inhibitor IGF-binding protein-3 by p53. Nature 377: 646-649, 1995.
21. Rajah R, Valentinis B and Cohen P, Insulin like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272: 12181-12188, 1997.
22. Ludwig RL, Bates S and Vousden KH, Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 16: 4952-4960, 1996.
23. Ryan KM and Vousden KH, Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 18: 3692-3698, 1998.
24. Aurelio ON, Cajot J-F, Hua ML-H, Khwaja Z and Stanbridge EJ, Germ-line-derived hinge domain p53 mutants have lost apoptotic but not cell cycle arrest functions. Cancer Res 58: 2190-2195, 1998.
25. Goi K, Takagi M, Iwata S, Delia D, Asada M, Donghi R, Tsunematsu Y, Nakazawa S, Yamamoto H, Yokota J, Tamura K, Yoshifumi S, Utsunomiya J, Takahashi T, Ueda R, Ishioka C, Eguchi M, Kamata N and Mizutani S, DNA damage-associated dysregulation of the cell cycle and apoptosis control in cells with germ-line p53 mutation. Cancer Res 57: 1895-1902, 1997.
26. Zhang H, Somasundaram K, Peng Y, Tian H, Bi DK, Weber BL and El-Deiry WS, BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16: 1713-1721, 1998.
27. Lill NL, Grossman SR, Ginsberg D, DeCaprio J and LivingSton DM, Binding and modulation of p53 by p300/CBP coactivators. Nature 387: 823-827, 1997.
28. Sang NL, Avantaggiati ML and Giordano A, Roles of p300, pocket proteins, and hTBP in E1A-mediated transcriptional regulation and inhibition of p53 transactivation activity. J Cell Biochem 66: 277-285, 1997.
29. Lee CW, Sorensen TS, Shikama N and LaThangue NB, Functional interplay between p53 and E2F through co-activator p300. Oncogene 16: 2695-2710, 1998.
30. Thomas A and White E, Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function. Genes Dev 12: 1975-1985, 1998.
31. Haupt Y, Maya R, Kazaz A and Oren M, Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
32. Chen L, Marechal V, Moreau J, Levine AJ and Chen J, Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. J Biol Chem 272: 22966-22973, 1997.
33. Gottlieb E and Oren M, P53 facilitates pRb cleavage in IL-3-deprived cells: Novel pro-apoptotic activity of p53. EMBO J 17: 3587-3596, 1998.
34. Quelle FW, Wang JL, Feng J, Wang D, Cleveland JL, Ihle JN and Zambetti GP, Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev 12: 1099-1107, 1998.
35. 1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 16: 3461-3469, 1998.
36. Israeli D, Tessler E, Haupt Y, Elkeles A, Wilder S, Amson R, Telerman A and Oren M, A novel p53-inducible gene, PAG608, encodes a nuclear zinc finger protein whose overexpression promotes apoptosis. EMBO J 16: 4384-4392, 1997.
37. Sheikh MS, Burns TF, Huang Y, Wu GS, AmundSon S, BrookS KS, Fornace AJ Jr and El-Deiry WS, p53-dependent and -independent regulation of the death receptor KILLER/ DR5 gene expression in response to genotoxic stress and tumor necrosis factor α. Cancer Res 58: 1593-1598, 1998.
38. Wu GS, Saftig P, Peters C and El-Deiry WS, Potential role for cathepsin D in p53-dependent tumor suppression and chemo-sensitivity. Oncogene 16: 2177-2183, 1998.
39. Yin YX, Terauchi Y, Solomon GG, Aizawa S, Rangarajan PN, Yazaki Y, Kadowaki T and Barrett JC, Involvement of p85 in p53-dependent apoptotic response to oxidative stress. Nature 391: 707-710, 1998.
40. PolyaK K, Xia Y, Zweier JL, Kinzler KW and Vogelstein B, A model for p53-induced apoptosis. Nature 389: 300-305, 1997.
41. Yonish-Rouach E, Deguin V, Zaitchouk T, Breugnot C, Mishal Z, Jenkins J and May E, Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene 11: 2197-2205, 1995.
42. Donatella Attardi L, Lowe S, Brugarolas J and Jacks T, Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 15: 3693-3701, 1996.
43. Sabbatini P, Han J, Chiou S-K, Nicholson DW and White E, interleukin 1β converting enzyme-like proteases are essential for p53-mediated transcriptionally dependent apoptosis. Cell Growth Differ 8: 643-653, 1997.
44. 2-terminal domain of p53. Int J Cancer 71: 858-866, 1997.
45. Zhu JH, Zhou WJ, Jiang JY and Chen XB, Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem 273: 13030-13036, 1998.
46. Sakamuro D, Sabbatini P, White E and Prendergast GC, The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogens 15: 887-898, 1997.
47. Almog N, Li R, Peled A, Schwartz D, Wolkowicz R, Goldfibnger N, Pei H and Rotter V, The murine C′-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Mol Cell Biol 17: 713-722, 1997.
48. Rowan S, Ludwig RL, Haupt Y, BateS S, Lu X, Oren M and Vousden KH, Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 15: 827-838, 1996.
49. Haupt Y, Rowan S, Shaulian E, Vousden KH and Oren M, Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev 9: 2170-2183, 1995.
50. Ishioka C, Englert C, Winge P, Yan YX, Engelstein M and Friend SH, Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian-cell assays in vivo. Oncogene 10: 1485-1492, 1995.
51. Caelles C, Helmberg A and Karin M, P53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223, 1994.
52. Yan Y, Shay JW, Wright WE and Mumby MC, Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation. J Biol Chem 272: 15220-15226, 1997.
53. Reinke V and Lozano G, The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene 15: 1527-1534, 1997.
54. Wang X, Vermeulin W, Coursen J, Gibson M, Lupold S, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers J and Harris C, The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 10: 1219-1232, 1996.
55. 2/M. Mol Cell Biol 16: 3884-3892, 1996.
56. Prisco M, Hongo A, Rizzo MG, Sacchi A and Baserga R, The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal. Mol Cell Biol 17: 1084-1092, 1997.
57. Ohlsson C, Kley N, Werner H and LeRoith D, P53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: Interaction between p53 and Sp1. Endocrinology 139: 1101-1107, 1998.
58. Teodoro JG and Branton PE, Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5. J Virol 71: 3620-3627, 1997.
59. Bennett M, Macdonald K, Chan S-W, Luzio JP, Simari R and Weissberg P, Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis. Science 282: 290-293, 1998.
60. Beletskaya IV, Nikonova LV and Beletsky IP, Cell cycle specificity of Fas-mediated apoptosis in WIL-2 cells. FEBS Lett 412: 91-93, 1997.
61. Beham A, Marin MC, Fernandez A, Herrmann J, Brisbay S, Tari AM, Lopez-Berestein G, Lozano G, Sarkiss M and McDonnell TJ, Bcl-2 inhibits p53 nuclear import following DNA damage. Oncogene 15: 2767-2772, 1997.
62. Aragane Y, Kulms D, Metze D, Wilkes G, Poppelmann B, Luger TA and Schwarz T, Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol 140: 171-182, 1998.
63. Miyake H, Hara I, Gohji K, Arakawa S and Kamidono S, P53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. Int J Oncol 12: 469-473, 1998.
64. wild-type cancer cells treated with ionizing radiation. Int J Cancer 73: 757-762, 1997.
65. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K and Debatin KM, Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 90: 3118-3129, 1997.
66. Williams BA, Makrigiannis AP, Blay J and Hoskin DW, treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells. Int J Cancer 73: 416-423, 1997.
67. Hueber A-O, Zörnig M, Lyon D, Suda T, Nagata S and Evan GI, Requirement for the CD95 receptor-ligand pathway in c-myc-induced apoptosis. Science 278: 1305-1309, 1997.
68. Zörnig M, Hueber A-O and Evan G, P53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice. Curr Biol 8: 467-470, 1998.
69. Fuchs EJ, McKenna KA and Bedi A, P53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32β. Cancer Res 57: 2550-2554, 1997.
70. Bennett MR, Evan GI and Schwartz SM, Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and -independent pathways. Circ Res 77: 266-273, 1995.
71. Harrington EA, Bennett MR, Fanidi A and Evan GI, C-Myc induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13: 3286-3295, 1994.
72. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A and Oren M, Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347, 1991.
73. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B and Costa J, induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89: 4495-4499, 1992.
74. Lotem J and Sachs L, Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82: 1092-1096, 1993.
75. Lotem J and Sachs L, Regulation of leukaemic cells by interleukin 6 and leukaemia inhibitory factor. Ciba Found Symp 167: 80-88, 1992.
76. Aladjem MI, Spike BT, Rodewald LW, Hope TJ, Klemm M, Jaenisch R and Wahl GM, ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 8: 145-155, 1998.
77. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CJ, Butel JS and Bradley A, Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221, 1992.
78. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP and Hall PA, The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54: 614-617, 1994.
79. Colombel M, Radvanyi F, Blanche M, Abbou C, Buttyan R, Donehower LA, Chopin D and Thiery JP, Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene 10: 1269-1274, 1995.
80. Symonds H, Krall L, Remington L, Saenz RM, Lowe S, Jacks T and VAN DT, P53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711, 1994.